Protagonist Therapeutics, Inc. (NASDAQ:PTGX) insider David Y. Liu sold 3,500 shares of the company’s stock in a transaction dated Monday, August 28th. The shares were sold at an average price of $15.00, for a total transaction of $52,500.00. Following the transaction, the insider now directly owns 5,500 shares of the company’s stock, valued at $82,500. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

David Y. Liu also recently made the following trade(s):

  • On Monday, July 10th, David Y. Liu sold 3,500 shares of Protagonist Therapeutics stock. The shares were sold at an average price of $12.68, for a total transaction of $44,380.00.

Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) traded up 12.32% during trading on Tuesday, hitting $16.77. 151,539 shares of the company traded hands. The company’s market capitalization is $283.45 million. Protagonist Therapeutics, Inc. has a 52 week low of $8.00 and a 52 week high of $26.36. The company has a 50 day moving average price of $12.43 and a 200 day moving average price of $12.09.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its earnings results on Tuesday, August 8th. The company reported ($0.89) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by $0.70.

TRADEMARK VIOLATION NOTICE: This article was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.thecerbatgem.com/2017/08/29/protagonist-therapeutics-inc-ptgx-insider-david-y-liu-sells-3500-shares.html.

Several equities analysts recently issued reports on PTGX shares. Zacks Investment Research upgraded shares of Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 10th. BMO Capital Markets boosted their price target on shares of Protagonist Therapeutics from $34.00 to $45.00 and gave the company an “outperform” rating in a research report on Wednesday, May 31st. BTIG Research started coverage on shares of Protagonist Therapeutics in a research report on Friday, July 21st. They set a “buy” rating and a $36.00 price target on the stock. Finally, ValuEngine upgraded shares of Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $26.00.

A number of hedge funds have recently modified their holdings of PTGX. Teachers Advisors LLC boosted its stake in shares of Protagonist Therapeutics by 17.7% in the fourth quarter. Teachers Advisors LLC now owns 9,461 shares of the company’s stock valued at $208,000 after buying an additional 1,424 shares during the period. State Street Corp boosted its stake in shares of Protagonist Therapeutics by 50.8% in the fourth quarter. State Street Corp now owns 92,163 shares of the company’s stock valued at $2,028,000 after buying an additional 31,042 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Protagonist Therapeutics by 15.1% in the first quarter. Bank of New York Mellon Corp now owns 26,148 shares of the company’s stock valued at $335,000 after buying an additional 3,433 shares during the period. FMR LLC boosted its stake in shares of Protagonist Therapeutics by 0.4% in the first quarter. FMR LLC now owns 2,518,198 shares of the company’s stock valued at $32,258,000 after buying an additional 11,031 shares during the period. Finally, Vanguard Group Inc. boosted its stake in shares of Protagonist Therapeutics by 3.8% in the second quarter. Vanguard Group Inc. now owns 325,395 shares of the company’s stock valued at $3,680,000 after buying an additional 11,881 shares during the period. 48.19% of the stock is currently owned by hedge funds and other institutional investors.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.

Receive News & Stock Ratings for Protagonist Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics Inc. and related stocks with our FREE daily email newsletter.